SMSabine Merkelbach-Bruse

Sabine Merkelbach-Bruse

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sabine Merkelbach-Bruse has a total of 93 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Expanded molecular routine testing for targetable mutations in non-small cell lung cancer to reveal frequent co-occuring mutations.

    by Anna Kostenko, Jana Fassunke, Susanne Steinhauser, Matthias Scheffler, Sabine Merkelbach-Bruse, Sebastian Yves Friedrich Michels, Rieke Nila Fischer, Lucia Nogova, Martin Hellmich, Thomas Zander, et al.

    E20596 Background: Using next-gen sequencing of predefined gene panels in routine clinical diagnostics of lung cancer allows, in contrast to single-gene assays, assessment of co-occuring mutations, which might underly heterogeneity of response to targeted drugs and survival. The Network Genomic Medicine (NGM) performs high sensitive next generation sequencing (NGS) based routine molecular diagnostics on a central platform for about 5000 inoperable lung cancer patients (pts) annually in Germany. Methods: NGS panel used in NGM consists of 17 genes to cover potentially targetable aberrations. Mutation analyses were run on an Illumina (MySeq) platform, while FISH analyses were performed separately. In 2016, we have started the evaluation of all NGM pts with available clinical data who had received NGS-based molecular diagnostics. In particular, we have focused on non-squamous (non-sq) and squamous (sq) NSCLC pts with co-occurring mutations: their frequency, significance and impact on overall survival. Results: From 2014 molecular genotyping was performed for 7,893 NGM pts (n = 7,246 NSCLC (5,667 non-sq and 1,487 sq pts) and n = 489 SCLC) with eligible clinical data. Genetic alterations in transformation-associated pathways were found in 79 % of all NSCLC pts. Furthermore, co-occurring mutations were detected in 39 % of these pts: 40 % in non-sq and 37 % in sq NSCLC. 11 % of pts had more than 2 co-occurring mutations. 1 % of all pts had 5 co-occurring mutations. The most frequent paired mutations were KRAS, EGFR and MET each with TP53 in non-sq and FRGF1 and TP53 in sq NSCLC. The incidences and significance of 3, 4 and 5 co-mutations as well as the impact of these co-occurring mutations on overall survival will be presented. Conclusions: Frequent occurrence of co-occuring mutations in transformation – associated pathways underlines the genetic heterogeneity also of lung cancer with classical driver mutation and the impact of co-occurring mutations on survival. This work confirms the use of molecular multiplex testing in routine molecular diagnostics of NSCLC. Assessment of co-occuring mutations will help to further specify genetically defined subgroups of lung cancer with therapeutic relevance.

  • Molecular panel sequencing of pre-treatment samples to reveal mechanisms of innate resistance to 3rd generation EGFR TKI treatment in T790M-positive NSCLC patients.

    by Sebastian Yves Friedrich Michels, Carina Heydt, Barbara Deschler-Baier, Vanessa Ruesseler, Jan Stratmann, Susanne Steinhauser, Rieke Nila Fischer, Matthias Scheffler, Jana Fassunke, Lucia Nogova, et al.

    9041 Background: Resistance to early generation epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKI) inevitably develops in EGFR-mutant lung cancer. The secondary EGFR p.T790M mutation is the driving factor in 60% of cases and 3rd generation EGFR TKIs have been developed to overcome T790M-mediated resistance. However, besides T790M other genetic aberrations such as amplifications of MET may contribute to resistance to EGFR inhibition in the same patient. We here report on the systematic analysis of co-occurring genetic aberrations that may influence response to 3rd generation EGFR TKIs. Methods: Thirty-six patients were treated with 3rd generation EGFR TKIs in the setting of acquired resistance to EGFR inhibition in cancer centers in Germany and Switzerland. Pre-treatment samples were analyzed for co-occurring genetic aberrations in a subset of resistance-related genes including MET, HER2, RAS-gene family, PIK3CA, CTNNB1 and PTEN using next-generation sequencing and fluorescence in-situ hybridization assays. We investigated the association between clinical, epidemiological and molecular data and response to treatment (RECIST 1.1). Results: Co-occurring genetic aberrations were found in 68% of the pre-treatment samples where both, analyses by sequencing and FISH were feasible (N = 25). Efficacy of 3rd generation EGFR TKIs significantly dropped in the presence of high-level MET amplification as compared to wild-type MET (ORR, 0.0%; 95% CI, 0.0-60.4 vs. 70.0%; 95% CI, 45.7-87.2; p = 0.02; median PFS, 1.0 month; 95% CI, 0.37-1.72 months vs. 8.2 months; 95% CI, 1.69-14.77 months; p ≤ 0.001). No statistically significant association was found between treatment efficacy and the molecular status of the genes analyzed or the number of prior EGFR TKIs. Conclusions: Prevalence of additional genetic aberrations is frequent in the setting of acquired resistance to early generation EGFR TKIs and may not necessarily mediate resistance to 3rd generation EGFR TKIs. However, in our analysis high-level amplification of MET was associated with primary treatment failure and might be the main factor underlying resistance in this setting.

  • Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations.

    by Alessandra Holzem, Lucia Nogova, Michaela A. Ihle, Claudia Wompner, Elisabeth Bitter, Sebastian Yves Friedrich Michels, Rieke Nila Fischer, Anna Kron, Ulrich Gerigk, Jens Kern, et al.

    E20059 Background: MAP2K1 mutations are rare in non-small cell lung cancer (NSCLC) and considered to be mutually exclusive with known driver mutations. Activation of the MEK1-cascade might play a pivotal role in resistance to targeted inhibition of BRAF V600E, EML4-ALK and EGFR T790M. So far, however, only MAP2K1 K57N could be identified and linked functionally to resistance in preclinical models. Clinical trials combining specific inhibitors for predefined NSCLC subgroups with MEK inhibitors are ongoing. We sought to characterize frequency and type of MAP2K1-mutated NSCLC regarding curated targetable aberrations. Methods: Tumor tissue collected consecutively from 4590 NSCLC patients within the German Network Genomic Medicine (NGM) between 07/2014 and 07/2015 was analyzed for MAP2K1 mutations using next-generation sequencing (NGS) with a set of 102 amplicons in 14 genes. Clinical and molecular characteristics of these patients were determined and compared with an internal control group of NSCLC patients and an independent control group of The Cancer Genome Atlas (TCGA). Results: We identified 21 (0.5%) patients with MAP2K1 mutations. They were frequently found in adenocarcinomas (n = 20) and were significantly associated with smoking. The most common MAP2K1 mutation was K57N. Most of the patients (n = 16) had additional oncogenic driver aberrations, including mutations in ALK, EGFR or BRAF, ROS1 rearrangements and MET amplification. TP53 mutations were found in 11 patients. In only five patients (23.8%) MAP2K1 occurred exclusively. TCGA analysis revealed additional 10 patients with MAP2K1 mutations, whereof 9 had additional TP53 mutations and one had BRAF mutation. Whereof most patients in our cohort had stage IV NSCLC, all patients in TCGA were systemic treatment naive. Compared with local stages in TCGA, our findings strongly suggest that targetable co-occurring mutations might occur more frequently in advanced stage NSCLC patients. Conclusions: MAP2K1 mutations co-occur frequently with targetable aberrations in smoking stage IV patients. Combination of targeted therapy against known driver aberrations with MEK inhibitors might be a promising therapeutic approach for such patients.

  • Survival following implementation of next-generation sequencing in routine diagnostics of advanced lung cancer: Results of the German Network Genomic Medicine.

    by Anna Kostenko, Sebastian Yves Friedrich Michels, Jana Fassunke, Matthias Scheffler, Sabine Merkelbach-Bruse, Rieke Nila Fischer, Merle Gerigk, Juliane Sueptitz, Florian Kron, Jan Peter Glossmann, et al.

    9085 Background: The Network Genomic Medicine (NGM) Lung Cancer is a health care provider network offering comprehensive next generation sequencing (NGS)-based multiplex genotyping on a central diagnostics platform in Cologne for inoperable lung cancer patients (pts) in Germany. Methods: The NGS panel used consists of 14 genes and 102 amplicons to cover potentially targetable aberrations. Mutation analyses were run on an Illumina (MySeq) platform, FISH analyses were performed separately. In 2015, we have started the second outcome evaluation for all NGM pts who had received NGS-based molecular diagnostics. In particular, we have focused on pts with activating EGFR mutation (EGFR+), ALK translocation (ALK+), BRAF-V600E mutation (BRAF+), HER2 amplification (HER2+) and ROS1 translocation (ROS1+) and on the outcome of pts treated in clinical trials (ct). Results: From 2013-2015 6210 lung cancer pts (n = 4244 non-squamous NSCLC) were genotyped. Overall survival (OS) is shown for 934 NSCLC pts including 110 pts treated in ct. For 108 EGFR+ pts, the OS of pts treated in ct with different 3rd generation EGFR-TKIs was 55 months (n = 25) vs 22 months in the control group (n = 83) (p = 0,002; mean OS: 29 months; 95%CI: 36-83 months). For 85 ALK+ pts, the OS of pts treated in ct with next-generation ALK-inhibitor after crizotinib failure was 35 months (n = 19) compared to OS of 23 months for 45 pts treated with crizotinib only and 8 months for 19 pts treated with no ALK inhibitors (p < 0,0001; mean OS: 22 months; 95%CI: 22-33 months). For 32 BRAF+ pts and 11 HER2+ pts, the mean OS was 23 months (95%CI: 12-26 months) and 25 months (95%CI: 15-34 months) (p = 0,022). The mean OS of 13 ROS1+ pts was not reached (95%CI: 58-100 months). Conclusions: Here we show successful implementation of NGS-based molecular diagnostics in clinical routine use. Moreover, molecular diagnostics triggers personalized therapy in – and outside clinical trials and improves survival for EGFR+, ALK+, ROS1+, BRAF+ and HER2+ pts. In particular, the use of next-gen. inhibitors after failure of first gen. inhibitors in EGFR+ and ALK+ pts leads to a significant and substantial additional survival benefit.


  • Genetic heterogeneity of KRAS-mutated NSCLC: Co-occurrence of potentially targetable aberrations and evolutionary background.

    by Matthias Scheffler, Michaela A. Ihle, Rebecca Hein, Sabine Merkelbach-Bruse, Johannes Braegelmann, Andreas H. Scheel, Sebastian Yves Friedrich Michels, Frank Ueckeroth, Anna Eisert, Leonie Gogl, et al.

    9018 Background: KRAS mutations in non-small cell lung cancer (NSCLC) still remain therapeutically untargetable. Assuming that these mutations are not mutually exclusive with other driver aberrations, we set out this study in order to describe and analyze co-occurring mutations and their potential therapeutic impact. In a subset of patients with co-occuring driver mutations, we performed additionally whole-exome sequencing (WES) to define clonal and evolutional status of the mutations. Results were compared with data from The Cancer Genome Atlas' (TCGA) for NSCLC. Methods: In a timeframe of 20 months, 4507 patients of a local screening initiative (Network Genomic Medicine Lung Cancer) were analyzed using next-generation parallel sequencing (NGS). The NGS panel consisted of 102 amplicons and 14 genes: KRAS, PIK3CA, BRAF, EGFR, ERBB2, NRAS, DDR2, TP53, ALK, CTNNB1, MET, AKT1, PTEN and MAP2K1. In subsets of patients, fluorescence in-situ hybridization (FISH) was performed for MET, FGFR1, and HER2 amplification and for RET, ALK and ROS1rearrangements. Clinical parameters, therapy, survival and smoking status were also collected. Results: We identified 1207 patients (26.8%) harboring a KRAS mutation, whereof 1080 patients (89.5%) underwent the complete diagnostic panel. The most common mutation was G12C accounting for 41.2%. In a total of 308 patients (28.8%) additional aberrations could be detected, including MET (prevalence 15.3%), FGFR1 (5.0%) and HER2 (12.7%) amplification and mutations in PIK3CA (3.4%), DDR2 (4.4%), PTEN (1.9%), CTNNB1 (1.7%), BRAF (1.3%) and EGFR (1.4%). Less frequently, mutations within NRAS, AKT1, ALK, MET, and MAP2K1 could be detected. 459 patients (42.9%) had co-occurring TP53mutations.. WES on selected cases confirmed the presence of these mutations. Conclusions: To our knowlege our data represent the largest analysis of co-occuring mutations in KRAS- mutated NSCLC. They show that KRAS-mutated NSCLC represents a heterogenous group of tumors with a substantial portion harboring a wide spectrum of additional targetable mutations. Further studies will show whether these findings translate into new therapeutic options in KRAS-mutated NSCLC.


  • Open Access

    Reactive lymphoid hyperplasia of the ocular surface: clinicopathologic features and search for infectious agents

    by Martina C. Herwig, Jana Fassunke, Sabine Merkelbach‐Bruse, Frank G. Holz, Hans‐Peter Fischer, Karin U. Loeffler


  • Open Access

    qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL

    by Jana Fassunke, Marie-Christine Blum, Hans-Ulrich Schildhaus, Marc Zapatka, Benedikt Brors, Helen Künstlinger, Reinhard Büttner, Eva Wardelmann, Sabine Merkelbach-Bruse

    Background: Gastrointestinal stromal tumors (GIST) represent the most common mesenchymal tumors of the gastrointestinal tract. About 85% carry an activating mutation in the KIT or PDGFRA gene. Approximately 10% of GIST are so-called wild type GIST (wt-GIST) without mutations in the hot spots. In the present study we evaluated appropriate reference genes for the expression analysis of formalin-fixed, paraffin-embedded and fresh frozen samples from gastrointestinal stromal tumors. We evaluated the gene expression of KIT as well as of the alternative receptor tyrosine kinase genes FLT3, CSF1-R, PDGFRB, AXL and MET by qPCR. wt-GIST were compared to samples with mutations in KIT exon 9 and 11 and PDGFRA exon 18 in order to evaluate whether overexpression of these alternative RTK might contribute to the pathogenesis of wt-GIST. Results: Gene expression variability of the pooled cDNA samples is much lower than the single reverse transcription cDNA synthesis. By combining the lowest variability values of fixed and fresh tissue, the genes POLR2A, PPIA, RPLPO and TFRC were chosen for further analysis of the GIST samples. Overexpression of KIT compared to the corresponding normal tissue was detected in each GIST subgroup except in GIST with PDGFRA exon 18 mutation. Comparing our sample groups, no significant differences in the gene expression levels of FLT3, CSF1R and AXL were determined. An exception was the sample group with KIT exon 9 mutation. A significantly reduced expression of CSF1R, FLT3 and PDGFRB compared to the normal tissue was detected. GIST with mutations in KIT exon 9 and 11 and in PDGFRA exon 18 showed a significant PDGFRB downregulation. Conclusions: As the variability of expression levels for the reference genes is very high comparing fresh frozen and formalin-fixed tissue there is a strong need for validation in each tissue type. None of the alternative receptor tyrosine kinases analyzed is associated with the pathogenesis of wild-type or mutated GIST. It remains to be clarified whether an autocrine or paracrine mechanism by overexpression of receptor tyrosine kinase ligands is responsible for the tumorigenesis of wt-GIST.


  • Molekulare Methoden in der Sarkomdiagnostik

    by Pd Dr. Rer.Nat. S. Merkelbach-Bruse, E. Wardelmann, H. Künstlinger, R. Büttner, H.-U. Schildhaus

    The use of modern molecular techniques has gained importance in the diagnosis of sarcomas in recent years. Each of the analytical methods discussed here has its unique advantages and specific requirements. Cytogenetic screening methods which provide genome-wide information depend on the availability of fresh tissue. With the aid of fluorescence in situ hybridization and RT-polymerase chain reaction, specific events such as translocations in Ewing sarcoma, synovial sarcoma or alveolar rhabdomyosarcoma, as well as gene amplifications in well-differentiated and dedifferentiated liposarcoma or radiation-induced angiosarcoma and deletions in rhabdoid tumors or well-differentiated spindle cell liposarcoma can be detected in fresh and formalin fixed tissues. Molecular methods including Sanger sequencing, pyrosequencing and high resolution melting provide information about specific molecular aberrations on gene level. Here we review the most important molecular techniques currently used in sarcoma diagnosis, describe their relevance for differential diagnosis and point out specific examples.


  • Open Access

    Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors

    by Sabine Merkelbach-Bruse, Wolfgang Dietmaier, Laszlo Füzesi, Andreas Gaumann, Florian Haller, Julia Kitz, Antje Krohn, Gunhild Mechtersheimer, Roland Penzel, Hans-Ulrich Schildhaus, et al.

    Mutation analysis of KIT and PDGFRA genes in gastrointestinal stromal tumors is gaining increasing importance for prognosis of GISTs and for prediction of treatment response. Several groups have identified specific mutational subtypes in KIT exon 11 associated with an increased risk of metastatic disease whereas GISTs with PDGFRA mutations often behave less aggressive. Furthermore, in advanced GIST disease with proven KIT exon 9 mutation the doubled daily dose of 800 mg imatinib increases the progression free survival and is now recommended both in the European and the American Guidelines. In Germany, there are still no general rules how to perform mutational analysis.


  • Multiple gastrointestinale Stromatumoren – Metastasen oder Koinzidenz?

    by Michael Majores, Jana Fassunke, Sabine Merkelbach-Bruse, Reinhard Büttner, Eva Wardelmann

    Epidemiologie Gastrointestinale Stromatumoren (GIST) sind die häufigsten mesenchymalen Tumoren des Gastrointestinaltrakts. Die meisten GIST sind im Magen lokalisiert, gefolgt von Manifestationen im Dünndarm [ 1 ]. Demgegenüber sind Dickdarm – hier zumeist das Rektum – oder Ösophagus weitaus seltener betroffen. Das mittlere Erkrankungsalter liegt im 6. und 7. Lebensjahrzehnt. Erkrankungen bei jüngeren Patienten sind demgegenüber seltener [ 1 ] [ 2 ]. Man rechnet im deutschsprachigen Raum mit ca. 1200 Neuerkrankungen pro Jahr [ 3 ]. Pathologie Pathogenese. Bei den meisten GIST-Tumoren (in 80 – 85 % der Fälle) spielen aktivierende Mutationen im kit-Gen eine wesentliche Rolle [ 4 ]. Etwa 5 – 10 % der Tumoren weisen demgegenüber Mutationen im PDGF-Rezeptor-α-(PDGFRA-)Gen auf [ 5 ]. Beide Gene kodieren für Rezeptor-Tyrosinkinasen. Wie es zu diesen Mutationen kommt, ist bislang nicht geklärt. Bei dem Großteil der Patienten handelt es sich um sporadische, also erworbene Mutationen, welche nur im Tumorgewebe, jedoch nicht im Normalgewebe nachweisbar sind. Nur sehr selten kommen familiäre GIST-Fälle aufgrund von Keimbahnmutationen vor, des Weiteren treten GIST gehäuft bei Patienten mit Neurofibromatose Typ 1 auf. Wachstumsverhalten. GIST werden nur selten im Frühstadium entdeckt. Nicht selten haben die Tumoren zum Diagnosezeitpunkt schon eine beträchtliche Tumorgröße erreicht. Etwa die Hälfte der Patienten weist zum Diagnosezeitpunkt bereits Metastasen auf [ 6 ]. Hierbei handelt es sich in etwa 90 % um intraabdominelle Metastasierungswege, hauptsächlich hämatogen in die Leber und kavitär ins Peritoneum. Anders als bei Karzinomen ist eine lymphogene Metastasierung nur in Einzelfällen zu beobachten. Ebenfalls seltene extraabdominelle Metastasen betreffen hauptsächlich Knochen und Lunge. Zur Abschätzung des Metastasierungsrisikos bzw. des Risikos für einen Tumorprogress sind derzeit zwei Risikoklassifikationen (Tab. [ 1 ] [ 2 ]) etabliert [ 7 ] [ 8 ] [ 9 ]. In diesen wird zum einen die Tumorgröße, zum anderen die Mitoseaktivität des Tumors, in der aktuelleren Miettinen-Klassifikation zudem die Lokalisation berücksichtigt. Therapie Therapeutisch steht bei GIST die chirurgische Entfernung des Tumors an erster Stelle, da eine komplette chirurgische Entfernung (R0-Resektion) den wichtigsten prognostischen Faktor darstellt. Strahlentherapie und Chemotherapie im klassischen Sinne zeigen erfahrungsgemäß keine relevante Ansprechrate bei GIST bzw. kommen nur in bestimmten Situationen zur Anwendung (z. B. Strahlentherapie bei Knochenmetastasen) [ 10 ]. Seit einigen Jahren wird eine neue Wirkstoffgruppe erfolgreich zur Behandlung von GIST eingesetzt. Bei diesen sog. Target-Therapien kommen Tyrosinkinase- oder Multikinase-Inhibitoren wie Imatinib (Glivec) und Sunitinib (Sutent) zur Anwendung. Diese blockieren kompetitiv die Bindung von ATP an die kit-Rezeptor-Tyrosinkinase, indem sie sich zielgenau in die Bindungstasche der Tyrosinkinase für ATP einlagern [ 11 ] [ 12 ]. Molekularpathologische Diagnostik Eine detaillierte klinisch-pathologische Stadieneinteilung mittels präoperativer Bildgebung und pathologischer Aufarbeitung des Resektionsmaterials ist für das weitere therapeutische Vorgehen von großer Bedeutung. Zusätzlich sind molekularpathologische Untersuchungen zum Nachweis von Mutationen im kit- bzw. PDGFRA-Gen anzuraten und auch von den aktuellen internationalen NCCN- und ESMO-Guidelines zumindest für Intermediate- und High-Risk-GIST empfohlen [ 13 ] [ 14 ]. Lediglich in etwa 10 % der Fälle sind in beiden Genen keine Mutationen vorhanden oder bleiben mit den derzeit zur Verfügung stehenden molekularbiologischen Methoden unentdeckt. Klinische Konsequenzen. Neben der prognostischen Bedeutung für die Tumorbiologie besitzt die Mutationsanalyse auch eine prädiktive Relevanz bezüglich der Ansprechrate und der erforderlichen Dosierung der Therapie mit Imatinib. Die molekularbiologische Charakterisierung bei mehreren Tumormanifestationen kann zudem entscheidende Hinweise darauf geben, ob Metastasen oder mehrere synchrone GIST vorliegen. Da zum Diagnosezeitpunkt bereits etwa die Hälfte der GIST metastasiert hat, sind mehrere Tumormanifestionen keine Seltenheit. Die Unterscheidung zwischen Metastasen und der Koinzidenz unabhängiger Tumoren ist naturgemäß vor allem bei wenigen Läsionen für das weitere therapeutische Vorgehen von zentraler Bedeutung. Anhand der hier vorgestellten Kasuistik werden die Möglichkeiten der molekularpathologischen Diagnostik insbesondere zur Unterscheidung einer Metastasierung von koinzidenten GIST diskutiert.